The Immunological Profile of Adipose Mesenchymal Stromal/Stem Cells after Cell Expansion and Inflammatory Priming
- PMID: 39062566
- PMCID: PMC11275169
- DOI: 10.3390/biom14070852
The Immunological Profile of Adipose Mesenchymal Stromal/Stem Cells after Cell Expansion and Inflammatory Priming
Abstract
Background: AT-MSCs display great immunoregulatory features, making them potential candidates for cell-based therapy. This study aimed to evaluate the "RBC lysis buffer" isolation protocol and immunological profiling of the so-obtained AT-MSCs.
Methods: We established an immune-comparative screening of AT-MSCs throughout in vitro cell expansion (PM, P1, P2, P3, P4) and inflammatory priming regarding the expression of 28 cell-surface markers, 6 cytokines/chemokines, and 10 TLR patterns.
Findings: AT-MSCs were highly expandable and sensitive to microenvironment challenges, hereby showing plasticity in distinct expression profiles. Both cell expansion and inflammation differentially modulated the expression profile of CD34, HLA-DR, CD40, CD62L, CD200 and CD155, CD252, CD54, CD58, CD106, CD274 and CD112. Inflammation resulted in a significant increase in the expression of the cytokines IL-6, IL-8, IL-1β, IL-1Ra, CCL5, and TNFα. Depending on the culture conditions, the expression of the TLR pattern was distinctively altered with TLR1-4, TLR7, and TLR10 being increased, whereas TLR6 was downregulated. Protein network and functional enrichment analysis showed that several trophic and immune responses are likely linked to these immunological changes.
Conclusions: AT-MSCs may sense and actively respond to tissue challenges by modulating distinct and specific pathways to create an appropriate immuno-reparative environment. These mechanisms need to be further characterized to identify and assess a molecular target that can enhance or impede the therapeutic ability of AT-MSCs, which therefore will help improve the quality, safety, and efficacy of the therapeutic strategy.
Keywords: Toll-like receptors; adipose tissue; cell passaging; cell therapy; cytokines; immune biology; inflammation; mesenchymal stromal/stem cells; red blood cell lysis buffer; regenerative medicine.
Conflict of interest statement
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Figures
References
-
- Merimi M., El-Majzoub R., Lagneaux L., Moussa Agha D., Bouhtit F., Meuleman N., Fahmi H., Lewalle P., Fayyad-Kazan M., Najar M. The Therapeutic Potential of Mesenchymal Stromal Cells for Regenerative Medicine: Current Knowledge and Future Understandings. Front. Cell Dev. Biol. 2021;9:661532. doi: 10.3389/fcell.2021.661532. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
- IAP-HEPRO BELSPO/Belgium from the Generation Life Foundation, Fonds Lambeau-Marteaux, Fonds National de la Recherche Scientifique (FNRS), PDR, Télévie, Les Amis de l'Institut Jules Bordet, the Scientific Re-search Foundation Flanders (FWO), the Research Council (OZR) of t
- SOG-20-0000000046/Canada, from La Chaire en Arthrose de l'Université de Montréal, The Arthritis Society
- PJT 175-1110/The Canadian Institutes of Health Research
LinkOut - more resources
Full Text Sources
Research Materials
